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Piracetam, the prototype of the so-called nootropic drugs’ is used since many years in different 
countries to treat cognitive impairment in aging and dementia. Findings that piracetam enhances 
fluidity of brain mitochondrial membranes led to the hypothesis that piracetam might improve 
mitochondrial function, e.g., might enhance ATP synthesis. This assumption has recently been 
supported by a number of observations showing enhanced mitochondrial membrane potential, 
enhanced ATP production, and reduced sensitivity for apoptosis in a variety of cell and animal 
models for aging and Alzheimer disease. As a specific consequence, substantial evidence for 
elevated neuronal plasticity as a specific effect of piracetam has emerged. Taken together, this 
new findings can explain many of the therapeutic effects of piracetam on cognition in aging 
and dementia as well as different situations of brain dysfunctions.
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observed at concentrations also needed in pharmacological experi-
ments to improve cognition (Saletu et al., 1995), we proposed that 
by restoring age-related membrane alterations piracetam improves 
brain function and finally cognition.
Piracetam’s improving effects on the fluidity of aged synapto-
somal membranes could explain the beneficial effects of piracetam 
on age-related deficits on several mechanisms of signal transduc-
tion such as receptor density and function, and transmitter release, 
since these mechanisms are disturbed in the aging brain probably 
due to a decrease of membrane fluidity (Stoll et al., 1992; Viana 
et al., 1992; Cohen and Muller, 1993; Scheuer et al., 1999). On the 
other hand, initial evidence that piracetam’s beneficial effects on 
the fluidity of aged mitochondrial membranes could contribute 
to its therapeutic efficacy originated from observations that pira-
cetam could improve glucose uptake and utilization as well as ATP 
production (Domanska-Janik and Zaleska, 1977; Heiss et al., 1988; 
Dormehl et al., 1999; Keil et al., 2006). These effects led to the term 
“metabolic enhancer,” sometimes used to characterize piracetam 
and related nootropics (Malik et al., 2007). However, the mecha-
nism of these effects and its possible relationship to mitochondrial 
function remained obscure.
As a specific feature of piracetam and other similar compounds, 
beneficial effects on cognition are usually associated with impaired 
brain function such as aging, hypoxia, glucose deprivation, injuries, 
or even neurodegeneration. Thus, young healthy animals or men 
usually benefit less from piracetam indicating that this compound 
is not a “cognition booster” or a drug for neuro-enhancement. As 
all the pathological conditions mentioned above are typically asso-
ciated with the vicious cycle between enhanced oxidative stress – 
elevated reactive oxygen species (ROS) production –   mitochondrial 
IntroductIon
Piracetam, the prototype of the so-called “nootropic” drugs is used 
in many countries to treat cognitive impairment in aging, brain 
injuries, as well as dementia (Muller et al., 1999; Winblad, 2005). A 
recent meta-analysis of all available (published and not published) 
clinical studies provided compelling evidence for the global efficacy 
of piracetam in a diverse group of older subjects with cognitive 
impairment (Waegemans et al., 2002).
Similar to the situation in man, piracetam has also been shown 
to improve cognitive function in animals, but its mode of action is 
not yet finally known (Winblad, 2005). Findings that piracetam’s 
efficacy is usually associated with conditions of disturbed brain 
function like aging (young healthy animals usually benefit little or 
nothing from piracetam treatment) (Valzelli et al., 1980; Muller 
et al., 1997), has led to the speculation that piracetam’s mechanism 
of action is associated with biochemical deficits of the aged brain 
(Müller et al., 1994, 1999; Scheuer et al., 1999). This assumption 
was later supported by observations that piracetam specifically 
enhances membrane fluidity in aged brain material, showing no 
effect at all in membranes from young brains (Muller et al., 1997). 
This unique mechanism of action could be explained by the specific 
binding to the polar head-structures of membrane phospholip-
ids leading to a more flexible arrangement of the fatty acid side 
chain structure, which got more rigid due to lipid peroxidation in 
aging or other situations associated with enhanced oxidative stress 
(Peuvot et al., 1995). At the subcellular level, piracetam’s effects 
on membrane fluidity could be demonstrated for synaptosomal 
plasma membranes as well as for mitochondrial membranes of 
aged mouse brain and for brain membranes of Alzheimer patients 
(Eckert et al., 1999; Muller et al., 1999). Since these effects were 
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(MCI) and manifests during the disease process (Selkoe, 2002). 
Mitochondria are key players in synaptic plasticity providing the 
necessary energy (Mattson et al., 2008). The observed mitochon-
drial deficits result in enhanced oxidative stress. Importantly, mito-
chondrial dysfunction and reduced bioenergetics occur early in 
pathogenesis and precede the development of plaque formation 
(Hauptmann et al., 2009).
PharmacologIcal strategIes to ImProve 
mItochondrIal functIon In agIng or ad
While the concept of Aß-induced mitochondrial dysfunction as a 
major functionally relevant pathomechanism in AD has received 
substantial support over the last decade, improving mitochondrial 
function as a target for new drug development has rather not, as 
most interest has been directed to drugs leading to reduced Aß 
load (Lemere et al., 2004). However, as several compounds out of 
those disease-modifying drug classes have recently failed to show 
clinical effectiveness in AD trials (Gura, 2008), a report about sub-
stantial therapeutic effects of dimebon in a 1-year clinical trial 
(Doody et al., 2008) received large attention. Quite interestingly, 
although originally used as an antihistaminic drug, dimebon was 
later characterized as a mitochondrial stabilizer with rather similar 
properties as reported for piracetam in the present communica-
tion (Bachurin et al., 2003; Bernales et al., 2008). The concept of 
using mitochondrial protection as treatment strategy for dementia 
has recently been further supported by a preliminary report about 
again substantial clinical improvement in AD patients treated with 
methylene blue (Gura, 2008). Importantly, this drug not only has 
been shown to enhance cognitive functions in several animal studies 
associated with elevated oxygen consumption, but also seems to 
enhance mitochondrial function by activating complex I and IV 
activities at the cellular level (Callaway et al., 2002; Callaway et al., 
2004; Atamna et al., 2008).
The close association and common basis of oxidative stress and 
mitochondrial dysfunction in brain aging and age-related neuro-
degenerative disorders like AD (see the previous chapters) explains 
that several antioxidants have a long history as possible treatments 
for AD and even have been and are used in this context. Initially 
mainly Vitamin E or Vitamin C or the combination of both was 
investigated (Bastianetto and Quirion, 2004; Farlow et al., 2008; 
Lee et al., 2009). While both at high concentrations definitively 
show antioxidant properties in vitro and in vivo, their therapeutical 
benefit to improve or even prevent cognitive impairment in the 
elderly is at present seen rather critically.
Another important class of naturally accruing antioxidant are 
flavonoids or other polyphenols, which also are fairly good antioxi-
dants which reduced oxidative stress in vitro and in vivo. Flavonoids 
also improve mitochondrial dysfunction and seem to have thera-
peutical benefit for long-term treatment of age-related cognitive 
impairment animals and men (Schmitt-Schillig et al., 2005; Schaffer 
et al., 2006). The significant reduction of the risk in getting AD by 
Mediterranean diet is very likely explained to an impotent part by 
the high daily intake of flavonoids (Scarmeas et al., 2006, 2007). In 
general, even if the effectiveness of those natural occurring antioxi-
dants to protect against AD seems to be limited, they seem to be 
the major players of diet in reducing oxidative stress and acting as 
a second however considerably weaker defense system.
damage – reduced energy supply – enhanced ROS production 
(Leuner et al., 2007; Mattson et al., 2008; Querfurth and LaFerla, 
2010), we speculated that piracetam might enhance mitochondrial 
function or at least protect against mitochondrial damage under 
such conditions but mainly in brain aging, or dementia. In both 
situations, similar but also variant alterations of mitochondrial 
function are present (Leuner et al., 2007; Müller et al., 2010), rep-
resenting possible targets and also plausible for therapeutic inter-
vention by piracetam (Müller et al., 2010).
mItochondrIal dysfunctIon and oxIdatIve stress In 
braIn agIng and alzheImer dIsease
Like other differentiated tissues, the central nervous system is 
profoundly affected by aging and reacts to aging by a decline of 
several physiological abilities including sensory, motor, emotional, 
or cognitive functions (Sastre et al., 2000; Floyd and Hensley, 2002; 
Balaban et al., 2005; Mattson and Magnus, 2006; Onyango et al., 
2010). Aging brain cells experience increasing amounts of oxida-
tive stress, perturbed energy homeostasis, accumulation of dam-
aged proteins, lesions in their nucleic acids and are characterized 
by impaired function of signaling mechanisms and altered gene 
expression. These changes were significantly exacerbated in neu-
rodegenerative disorders and amplified in vulnerable neuronal 
populations be disease related processes such as accumulation of 
damaged proteins, e.g., Amyloid-beta (Aß) levels in Alzheimer’s 
disease (AD) (Cleary et al., 2005; Haass and Selkoe, 2007; Selkoe, 
2008; Querfurth and LaFerla, 2010). Beside the described dysfunc-
tions, mitochondrial perturbations are strongly associated with 
aging. Mitochondria play a central role in producing ATP as the 
central source of cellular energy and are critical regulators of pro-
grammed cell death during aging (Sastre et al., 2000; Atamna, 2004; 
Balaban et al., 2005; Schuessel et al., 2006). Mitochondrial func-
tion becomes less efficient during brain aging including decreased 
activities of complex I and to a lesser content of complex IV of the 
respiratory chain, which in turn leads to enhanced ROS production, 
reduced Ca2+ buffering capacity, and accumulation of mitochon-
drial DNA (mtDNA) mutations (reviews for this topic (Mattson, 
2007; Mattson et al., 2008).
    Abnormalities in mitochondrial function and oxidative stress 
are also relevant for the pathogenesis of Alzheimer’s disease (AD) 
(Hauptmann et al., 2006; Anandatheerthavarada and Devi, 2007; 
Leuner et al., 2007; Moreira et al., 2007; Reddy and Beal, 2008). In 
the brain of AD patients, defective energy metabolism and early 
defects in glucose utilization were observed already many years 
before (Munch et al., 1998). Moreover, the AD brain is specifi-
cally marked by accumulation of the misfolded proteins Aß and 
hyperphosphorylated tau, both contributing together with aging-
related deficits to severe neurodegenerative alterations, such as the 
loss of synapses and neurons, atrophy, and the selective depletion 
of neurotransmitter systems (e.g., acetylcholine) in the hippoc-
ampus and cerebral cortex (Haass and Selkoe, 2007; Querfurth 
and LaFerla, 2010). At the mitochondrial level, complex I and 
complex IV seem to be specifically affected, where tau pathology 
mainly impairs complex I activity, and Aß complex IV activity 
(Eckert et al., 2008; Hauptmann et al., 2009; Rhein et al., 2009). 
One of the earliest changes observed in AD is synaptic failure 
which already starts in patients with mild cognitive impairment www.frontiersin.org  September 2010  | Volume 4  | Article 44  |  3
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Mattson et al., 2008) (Figure 1), but also since mitochondria are the 
relevant targets for their own production of free radicals (Figure 1). 
Accordingly, due to our initial findings of piracetam enhancing 
mitochondrial membrane fluidity (Eckert et al., 1999) and obser-
vations that membrane fluidity regulates mitochondrial function 
probably by enhancing the mobility and function of the complexes 
of the respiratory chain (Ricchelli et al., 1999; Muriel and Perez-
Rojas, 2003; Colell et al., 2004; Aleardi et al., 2005), we speculated 
that piracetam might enhance mitochondrial function or at least 
might protect mitochondria in situations of enhanced damage. 
To investigate this assumption, we used different cell models in 
tissue culture and induced experimentally oxidative stress using 
different approaches to mirror within hours or a few days what is 
usually seen in aged or diseased brains at the end of the life span. 
Mitochondrial function was assessed by monitoring mitochon-
drial membrane potential (MMP) using specific membrane dyes, 
by measuring ATP production, and the release of proapoptotic 
factors (Keil et al., 2006; Kurz et al., 2010)
Another case of a herbal drug is the standardized Ginkgo biloba 
extract (EGb 761), which has been used for many years as a pre-
scription or OTC drug in many countries to treat aging-related 
cognitive disorders including AD (Christen and Maixent, 2002). 
EGb 761 contains 24% of flavonoids and 6% of terpenens (Sastre 
et al., 2002; Abdel-Kader et al., 2007). While the flavonoid frac-
tion seems to be mainly responsible for the free radical scavenging 
properties, several terpene lactones (Ginkgolides, Bilobalide) show 
substantial  mitochondria-protecting  properties  (Abdel-Kader 
et al., 2007).
PIracetam
Oxidative stress usually accumulates in aged or diseased brain tis-
sue over years or even decades due to the vicious cycle between 
increased ROS, and enhanced mitochondrial dysfunction (Floyd 
and  Hensley,  2002).  Within  this  system,  mitochondria  play  a 
crucial role as their impaired function not only leads to reduced 
ATP production and finally enhanced apoptosis (Mattson, 2000; 
10000
15000
20000
25000
2-3 months 22 months
 control
 piracetam
500 mg kg-1
*
R
1
2
3
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
p
e
r
 
m
g
 
m
l
-
1
 
p
r
o
t
e
i
n
A B
C
Figure 1 | Piracetam reduces measures of mitochondrial dysfunction in 
NMri mice – higher sensitivity in aged mice 2–3 months old and 22–24 
months old NMri mice were treated for 14 days with 0.5 g piracetam/kg 
in 0.9% NaCi solution p.o. once daily for 2 weeks. Control animals 
received 0.9% NaCI solution alone. All data are modified after Keil 
et al. (2006). (A) Dissociated brain cells were isolated and MMP 
was detected. The MMP was significantly reduced in old animals 
(22 months) and protected by Piracetam. Data are expressed as 
mean ± SEM (n = 6–8) *p < 0.05 piracetam treated old animals vs. aged 
controls. (B,C) Effects of aging and treatment with piracetam on SOD, and 
GPx in young and old animals. Activities of antioxidant enzymes are increased 
in aged mice. Treatment with piracetam reduces the enzyme activities 
significantly in old mice. Data are expressed as mean ± SEM (n = 7). *p < 0.05 
piracetam treated old animals vs. aged controls.Frontiers in Neuroscience  |  Neuropharmacology    September 2010  | Volume 4  | Article 44  |  4
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after Aß1–42 substantially protected MMP at concentrations already 
beginning with 0.1 mM. Comparable protective effects of piracetam 
were observed for dissociated brain cells of Naval Medical Research 
Institute (NMRI) mice following incubation with fibrillar Aß1–42. In 
both cell types, piracetam alone has no effect on MMP.
ProtectIon agaInst oxIdatIve stress In dIssocIated braIn 
cells from subchronIcally treated mIce
After demonstrating piracetam’s efficacy in reducing mitochondrial 
dysfunction induced by several stressors in vitro, we also investi-
gated its protective effects following treatment of aged mice or 
mice transgenic for the Swedish human Amyloid Precursor Protein 
(APP) gene which express a substantial amount of Aß in the brains 
(tgAPP mice) (Keil et al., 2006; Kurz et al., 2010). The rational 
for using aged animals mainly originates from a large number 
of findings that piracetam’s efficacy to improve cognitive func-
tions usually is less pronounced in young healthy animals but gets 
much more prominent in aged animals (see Chapter 1.0). We used 
aged NMRI mice which are bread in our animal facilities not only 
showing clear cognitive impairment but also several measures of 
oxidative stress, and mitochondrial dysfunction at an age around 
20 months including a decreased MMP compared to young mice 
(Müller et al., 2010). Piracetam treatment for 14 days normalized 
MMP in aged mice, while similar treatment of young animals had 
no effect (Figure 1).
On the other hand, a similar piracetam treatment not only pro-
tected brain cells of aged but also young mice against oxidative 
stress induced in vitro by addition of H2O2, SNP, or Aß1–42. Even if 
brain cells of young mice treated with piracetam also showed some 
benefit from piracetam treatment, aged animals usually responded 
most (Figure 1).
Antioxidative enzymes are the primary defense mechanism to 
protect biological macromolecules from oxidative damage, and are 
upregulated in aged mouse brain as an adaptive response to oxida-
tive stress. Therefore, we investigated the effect of piracetam treat-
ment on the activities of superoxide dismutase (SOD), glutathione 
peroxidase (GPx), and glutathione reductase (GR) in young mice 
(2–3 months old) and old mice (22–24 months old). We confirmed 
a significant increase in GPx and GR activity in aged mice compared 
to young mice. The activity of SOD had also a tendency to increase 
with age. Piracetam treatment decreased the activities of all three 
enzymes in aged mice nearly to the level of young animals. In young 
mice, a only small and not significant decrease of antioxidative 
enzymes could be observed (Figure 1). Quite similar mitochondria 
protecting effects have recently been observed in mice following 
experimentally induced mitochondrial dysfunction (g-galactose) 
after treatment with piracetam (300 mg/kg, 14 days) at the levels 
of MMP, activities of complexes I–IV, and ROS generation (Zhang 
et al., 2010). Unfortunately, both studies did not report glutathione 
levels, which also has a relevant role in regulating mitochondrial 
function (Jha et al., 2000).
Isolated brain cells of mice overexpressing mutated human amy-
loid precursor protein (tgAPP) show significant reductions of MMP 
and ATP synthesis relative to non-transgenic littermate controls 
confirming previous observation from our group (Hauptmann 
et al., 2009). Similar piracetam treatment (0.5 g/kg/day orally) 
already described for NMRI mice above again showed substantial 
ProtectIon agaInst oxIdatIve stress in vitro
Beside the use of H2O2 in some initial experiments, we usually 
induced oxidative stress by the NO donor sodium nitroprusside 
(SNP), due to the important role of nitrosative stress in AD (Keil 
et al., 2004a,b). In PC12 cells, SNP, led to a reduction of MMP and 
ATP levels. Under basal conditions without additional SNP dam-
age, piracetam did not affect both alterations even at rather high 
concentrations. However, piracetam was able to reduce both meas-
ures of mitochondrial dysfunction after pre- and post-incubation 
(Keil et al., 2006).
Another stressor, serum deprivation also leads to a decrease 
of mitochondrial membrane potential (MMP) and a decrease of 
ATP levels in neurons. Additionally, serum like glucose deprivation 
in PC12 cells causes peroxidation of their cell membrane lipids, 
decreases intracellular SOD activity, and enhances apoptosis in 
PC12 cells (Keil et al., 2004b, 2006). Interestingly, piracetam was 
able to protect MMP against cellular stress following serum depri-
vation. Under conditions of mild serum deprivation, when serum 
concentrations not lower than 2% were used, piracetam (500 μM) 
induced a nearly complete recovery of MMP. Furthermore, reduced 
ATP levels were already seen at 10% serum. Under this condition, 
piracetam completely restored ATP levels, while at lower serum con-
centrations only a partial restoration was seen (Keil et al., 2006).
As mentioned before, complex I and complex IV functions are 
impaired in aging and AD. Thus, the possible efficacy of piracetam 
to protect individual complexes of the mitochondrial respiratory 
chain after treatment with specific complex inhibitors was also 
investigated. Complexes I, II, and III were already protected at 
concentrations as low as 500 μM piracetam, while a significant 
protection of complexes IV and V was observed at a concentration 
of 1000 μM piracetam (Keil et al., 2006). This broad activity of pira-
cetam is in line with the assumptions that improvement of complex 
activity might be due rather to its fluidity enhancing properties at 
mitochondrial membranes rather than by specific effects at the 
individual complexes. This is also supported by the data of Zhang 
et al. (2010) indicating enhanced activity of complexes I–IV in mice 
after induction of mitochondrial dysfunction with d-galactose. It is 
very important to note that the beneficial effects of piracetam have 
not only been seen at the level of MMP but also in using several 
other measures of mitochondrial function since MMP alterations 
are not always directly connected with changes of mitochondrial 
function (Cao et al., 2007; Kahlert et al., 2008).
As already mentioned, a major link between the mitochondrial 
defects of our brain accumulating during decades of aging and 
the specific Aß related toxicity in AD seems to be oxidative stress 
induced by Aß as well as Aß induced impairment of mitochon-
drial function, e.g., reduced activity of the complexes I and IV of 
the respiratory chain. This very slow process can experimentally 
be investigated by inducing mitochondrial dysfunction in cells in 
tissue culture following incubation with extracellularly applied Aß 
(Kurz et al., 2010). Since Aß1–42 is presently considered as the main 
toxic Aß species, we used this peptide and several experimental 
cell models (PC12 cells, HEK cells, dissociated mouse brain cells) 
to study possible protective effects of piracetam on mitochondrial 
deficits. When PC12 cells were treated with fibrillar Aß1–42 10 nM 
for 24 h a reduction of MMP was observed as described previously 
by our group (Keil et al., 2004a). The addition of piracetam 30 min www.frontiersin.org  September 2010  | Volume 4  | Article 44  |  5
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293 cells stably overexpressing human APP showing   moderately 
enhanced Aß levels (Keil et al., 2004a). Piracetam lowered Aß lev-
els under basal conditions (Kurz et al., 2010). In agreement with 
other findings (Guglielmotto et al., 2009) mitochondrial dysfunc-
tion induced with SNP elevates Aß1–40 levels substantially. Again, 
treatment with piracetam lowered Aß significantly by 15–20% 
(Figure 3). In addition, piracetam improves mitochondrial func-
tion under the same conditions in APPwt HEK 293 when Aß gen-
eration is decreased (Figure 3).
improvement of MMP and ATP production (Figure 2). As reported 
earlier (Blanchard et al., 2003), these mice express substantial level 
of soluble Aß in the brain while littermates do not. Quite interest-
ingly, piracetam treatment led to an about 25% reduction of soluble 
Aß (Kurz et al., 2010) (Figure 3). A related observation showing 
reduced Aß levels in the plasma of geriatric patients treated with 
piracetam was published by Blasko et al. (2005). In order to inves-
tigate if this effect of piracetam on Aß levels might also be associ-
ated with improved mitochondrial function, we used APPwt HEK 
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Figure 2 | Piracetam improves measures of mitochondrial function in 
tgAPP mice. (A) Animals were treated for 14 days with 0.5 g piracetam/kg in 
0.9% NaCI solution p.o. once daily for 2 weeks. Control animals received 0.9% 
NaCI solution alone. All data are modified after Kurz et al. (2010). The MMP 
was significantly reduced in tgAPP mice. Piracetam treatment normalizes the 
MMP to non-tgAPP levels. Data are expressed as mean ± SEM (n = 7–8). 
+p < 0.05 control non-tgAPP vs. control tgAPP , *p < 0.01 piracetam treated 
tgAPP vs. tgAPP control; Student’s unpaired t-test. (B) ATP levels were 
also significantly impaired in tgAPP mice. In contrast, piracetam 
treatment increases ATP levels not only in tgAPP animals but also in 
control animals. Data are expressed as mean ± SEM (n = 7-8). 
*p < 0.05 control non-tgAPP vs. piracetam treated non-tgAPP; 
+p < 0.05 control non-tgAPP vs. control tgAPP , *p < 0.01 piracetam 
treated tgAPP vs. tgAPP control; Student’s unpaired t-test.
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Figure 3 | Piracetam ameliorates elevated Aβ production following 
mitochondrial dysfunction. (A) Normalized Aβ levels were quantified in brain 
homogenates from non-tg littermate and tgAPP mice (3 months old). **p < 0.01 
piracetam treated tgAPP vs. control tgAPP; student’s unpaired t-test. 
(B) Piracetam reduces nitrosative stress induced elevation of Aβ in APPwt 
HEK293 cells. Cells were preincubated for 24 h with piracetam (1 mM) and 
stressed for additional 24 h with SNP (0.5 mM). Data are expressed as 
mean ± SEM (n = 3–4). +++p < 0.001 APPwt HEK293 control cells vs. cells treated 
with SNP , *p < 0.01 APPwt HEK293 cells stressed with SNP 0.5 mM vs. stressed 
cells preincubated with piracetam; Student’s unpaired t-test. (C) Piracetam 
ameliorates nitrosative stress induced reduction of mitochondrial membrane 
potential. Cells were preincubated for 24 h with piracetam (1 mM) and stressed 
for additional 24 h with SNP (0.5 mM). Data are expressed as mean ± SEM (n = 6). 
All data are modified after Kurz et al. (2010). **p < 0.01 APPwt HEK293 cells 
stressed with SNP 0.5 mM vs. stressed cells preincubated with piracetam, 
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piracetam treatment. This was also the case for the adaptive eleva-
tion of antioxidant enzyme activities. When mild conditions were 
used in vitro (e.g. partial serum deprivation), a complete protec-
tion of mitochondrial function was seen by piracetam treatment 
in PC12 cells. Moreover, piracetam was highly effective in vivo in 
pathophysiologically relevant situations of brain dysfunction.
Piracetam does not possess radical scavenging properties (Keil 
et al., 2006). Thus, it seems quite likely that piracetam acts directly 
at the mitochondrial level, presumably by improving mitochondrial 
membrane properties. This is also supported by our observation 
that in several experiments protective effects were also seen in the 
recovery phase, when the oxidative stressor was already removed. 
Moreover, experiments from our lab also indicate comparable 
effects of piracetam on isolated mouse brain mitochondria of 
animals treated with piracetam. The concentrations of piracetam 
effective in vitro (100–1000 μM) and the doses used in the in vivo 
experiments (100–500 mg/kg) are quite well within the plasma 
concentrations seen in patients treated with the standard dose of 
about 5 g daily, which range between 200 and 2000 μM (Saletu et al., 
1995; Wang et al., 2010). Thus, it is quite likely that similar effects 
are also taking place in the brain of piracetam treated patients. 
Moreover, a recent pharmacokinetic study in rats indicates plasma 
concentrations around 500–1000 μmol/l at oral doses of 500 mg/
kg BW (Wang et al., 2010).
While the interaction of piracetam with neuronal membranes 
shows little changes of membrane properties under normal condi-
tions, it significantly enhances reduced membrane fluidity, for exam-
ple, in the aging or even Alzheimer brain. All the conditions associated 
with positive effects of piracetam on mitochondrial function in the 
experiments reviewed above also seem to be associated with decreased 
membrane fluidity mainly due to enhanced lipids peroxidation. Thus, 
it seems quite plausible that piracetam improves mitochondrial func-
tion by enhancing fluidity of   mitochondrial membranes, which seems 
to be a critical factor regulating mitochondrial function. However, 
direct proof for this mechanism still needs to be shown.
PIracetam amelIorates aß Induced ImPaIrment of neurItIc 
outgrowth
In agreement with the pronounced loss of neurites and synapses in 
AD brain as one of the functionally most relevant histopathologi-
cal lesions (Selkoe, 2002; Lacor et al., 2007), Aß peptides have been 
repeatedly demonstrated to reduce neuritic outgrowth in different 
neuronal cell lines in vitro including PC12 cells (Hirata et al., 2005; Hu 
et al., 2007; Evans et al., 2008). Oligomeric Aß seems to be more active 
than fibrillar Aß (Lacor et al., 2007; Evans et al., 2008). In agreement 
with these observations, the addition of oligomeric Aß1–42 (1 μM) to 
nerve growth factor (NGF) treated PC12 cells reduces neuritic length 
significantly. When the same experiment was carried out in the pres-
ence of piracetam (1 mM), the negative effect of oligomeric Aß1–42 
was completely inhibited. In agreement with the assumption that 
enhanced oxidative stress might explain the Aß induced reduction 
of neuritic outgrowth (Guglielmotto et al., 2009) treating PC12 cells 
with SNP reduced neuritic outgrowth even stronger. Again, piracetam 
ameliorates this negative effect significantly under conditions of opti-
mal NGF stimulation (Figure 4). A reduction of neuritic outgrowth 
depending on Aß load was also observed in our PC12 cells transgenic 
for human APP, where we observed a reduction of neuritic length, 
which could be substantially ameliorated by piracetam (Figure 4). 
The enhancing effect of piracetam was observed over the whole NGF 
concentration range (1–50 ng/ml) still leading to increased neuritic 
length under maximum NGF stimulation (Figure 4).
summIng uP
The data presented clearly show that piracetam protects mitochon-
dria against different conditions associated with oxidative stress 
including aging. Piracetam’s protecting effects on mitochondrial 
damage induced in vitro are small, but reproducible and highly sig-
nificant. This is not surprising, since the conditions used to induce 
oxidative stress in vitro are not pathophysiological but rather aggres-
sive, in contrast to the small and slowly   occurring changes induced 
by aging, which however were sometimes   completely reversed by 
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Figure 4 | Piracetam improves neuritogenesis following Aß exposure. 
(A) PC12 cells were treated over 6 days with NGF 50 ng/ml in the presence of 
oligomeric Aβ 1 μM. Piracetam 1 mM was added and the effects on neurite 
outgrowth were investigated. (B) APPsw PC12 cells were treated over 6 days 
with NGF 50 ng/ml in the presence or absence of piracetam 1 mM and neurite 
outgrowth was measured. In the presence of different NGF concentrations 
(1–50 ng/ml) piracetam improved the neurotrophic effect of NGF in APPsw cells. 
All data are modified after Kurz et al. (2010). Data are expressed as mean ± SEM 
(n = 6–7) **p < 0.01, ***p < 0.001 vs. the respective control, two-way anova 
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Two older studies have investigated the cognition improving effects 
of piracetam in young volunteers under mild hypoxia as a pharma-
cological model to mirror impaired brain function as seen in aging 
or dementia (Demay and Bande, 1980; Saletu et al., 1995). The data 
from Demay and Bande (1980) are given in Figure 5 showing con-
siderably less errors in a memory task under hypoxia following 5 days 
of piracetam treatment with 4.8 g per day, the average therapeutic 
dose even used today (Figure 5). Hypoxia induced cognitive but 
also biochemical and physiological deficits mirroring the situation in 
dementia has also been used in a very recent study in rats (He et al., 
2008). In this study, chronic cerebral hyperfusion was induced by 
ligature of bilateral common carotid arteries leading to acute but also 
subacute structural and functional brain deficits. Most importantly, 
spatial memory performance (Morris Water maze) was substantially 
impaired and showed pronounced improvement by piracetam treat-
ment (600 mg) per day starting after surgery (Figure 6). Besides 
reducing histopathologic markers of neuronal damage and reducing 
the expression of proapoptotic proteins, piracetam also improved 
long term potentiation in the CA3 region of the hippocampus of 
lesioned  animals  (Figure 7).  Together  with  data  that  piracetam 
reduces neuronal loss and improves synaptic reorganization after 
chronic alcohol consumption (Brandao et al., 1995; Brandao et al., 
1996) with findings of enhanced restitution and reorganization of 
cortical neuronal circuits after brain damage (Coq and Xerri, 1999; 
Xerri and Zennou-Azogui, 2003), and with findings that piracetam 
improves neuritic outgrowth after oxidative stress and/or Aß medi-
ated stress (Kurz et al., 2010), the findings of He et al. (2008) strongly 
support the concept that piracetam given chronically might improve 
many parameters of synaptic plasticity from LTP at the synaptic level, 
to enhanced neurite- as well as synaptogenesis at the structural level, 
and may even partially protect neurons from apoptosis.
The new concept that by improving mitochondrial function 
piracetam stimulates synaptic function and plasticity in situations 
of impaired brain function easily integrates many previous pre-
clinical findings see above and also data about clinical efficacy of 
piracetam in several not clearly related disease states.
•	 Cognitive	deficits	after	coronary	bypass	surgery	probably	cau-
sed by periods of mild hypoxia are well known and represent 
a serious impairment of those patients. Treatment with pira-
cetam has been shown in recent studies to reduce the severity 
of post surgery cognitive impairments (Uebelhack et al., 2003; 
Szalma et al., 2006; Holinski et al., 2008).
•	 Mild	cognitive	impairment	(MCI)	is	a	common	prodromal	
state for late dementia. Piracetam treatment has been shown 
to improve several aspects of cognition in such patients, which 
had been selected at the time of the study on the basis of the 
previous and somewhat different concept of AAMI (age asso-
ciated memory impairment) (Israel et al., 1994).
•	 Only	few	studies	have	been	conducted	in	specific	groups	of	patients	
with either Alzheimer type or vascular dementia. In most studies, 
mixed groups of demented patients were investigated. Nevertheless, 
cognitive improvement was seen under the treatment with pirace-
tam regardless of the type of dementia (Waegemans et al., 2002). 
Most of these studies however were rather short. In the only one 
1-year trial in AD patients, some evidence for a reduction of the 
cognitive decline over time was detected (Croisile et al., 1993), were 
translatIon Into effects on cognItIon In anImals 
and gerIatrIc PatIents
Piracetam was originally developed as a cyclic derivative of gam-
ma-aminobutyric acid (GABA) to treat anxiety. While it failed as 
an anxiolytic, it showed considerable efficacy in tests of “central 
nystagmus” as a model of vertigo, which at that time was only seen 
for antihistaminic and anticholinergic compounds. Piracetam 
not only did not have antihistaminic or anticholinergic proper-
ties, but even did not show any central activity like sedation, 
stimulation, or influence on autonomic function. However, as a 
rather new spectrum of pharmacological properties piracetam 
did facilitate interhemispheric transfer, enhanced the cerebral 
resistance to noxious stimuli like hypoxia and, most impor-
tantly, it enhanced or facilitated learning and other cognitive 
functions (Giurgea, 1982). These cognition improving proper-
ties still represent the basis of the present therapeutical use of 
piracetam in many countries all over the world in the whole 
spectrum of geriatric memory disorders, in cases of impaired 
cognitive functions after head injuries, and also in vertigo. Even 
if piracetam can facilitate learning and other cognitive functions 
under normal conditions (e.g., young healthy volunteers), it has 
been a most consistent observation over nearly three decades of 
piracetam’s clinical use that the cognition improving properties 
are much more pronounced when brain function is impaired 
such as aging, hypoxia, cerebral injuries, or Aß load in AD, condi-
tions which all have mitochondrial dysfunction as common final 
pathway. Since these preclinical and clinical data form the link 
between mitochondrial protection as major preclinical mecha-
nism of action and the clinical efficacy of piracetam in a large 
variety of diverse groups of older subjects with cognitive impair-
ment, some of these data will be reviewed shortly.
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Figure 5 | Piracetam improves cognitive function in men after hypoxia. 
The ability of 12 healthy volunteers to concentrate in a low oxygen pressure 
tank was assessed by measuring errors in a visual attention test in a 
placebo-controlled crossover trial in which volunteers were given 4.8 g 
piracetam daily for 4 days and 7 .2 g on the fifth day. Depending on the time of 
hypoxia, errors were observed. Error number was significantly reduced by 
piracetam treatment, especially for the longer hypoxic period. Data are 
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of  neuronal  function,  enhancement  of  cerebral  communi-
cation, and improvement of neuronal plasticity could be an 
important aspect for piracetams effects on vertigo, e.g., enhan-
cing the “cognitive aspects” of vertigo (Rosenhall et al., 1996; 
Oosterveld, 1999; Toupet, 2001).
•	 Even	in	myoclonus	as	in	movement	disorders	(Hanna and Bhatia, 
1997; Waldbaum and Patel, 2010), mitochondrial dysfunction 
seems to be part of the pathophysiological basis and might be 
the target of piracetam’s therapeutical benefit (Ikeda et al., 1996; 
Karacostas et al., 1999; Wolters and Benecke, 2009).
In conclusion, more than 30 years after the introduction of pira-
cetam the new findings of mitochondrial protection will allow a 
new perspective for this old nootropic and might explain its con-
sistent use in many countries around the world.
acknowledgment
The studies presented in this report and the publication costs were 
supported by an unrestricted research grant from UCB, Brussles 
(Belgium). 
the MMSE (minimental state evaluation did not change signifi-
cantly in the Piracetam group but showed the expected 3 point 
decline in the placebo group over the year.
•	 Structural	improvement	might	explain	the	therapeutical	bene-
fit in neurodevelopment disorders like dyslexia which is sup-
ported by several well controlled clinical trials (Wilsher, 1986; 
Wilsher et al., 1987; Ackerman et al., 1991).
•	 The	effectiveness	of	piracetam	in	experimental	models	of	cen-
tral nystagmus was one of the first observations about phar-
macological properties of piracetam (Giurgea, 1982). Even if 
this can be easily linked to its therapeutic use in vertigo, a plau-
sible explanation of the improvement of vertigo by   piracetam 
was not possible, especially since its effectiveness seems to be 
rather similar regardless the origin of vertigo. However, with 
the increasing awareness of higher brain regions for main-
taining  balance  and  preventing  vertigo  by  coordinating  all 
sensory  inputs  (Dieterich  and  Brandt,  2010),  improvement 
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Figure 6 | Piracetam improves cerebral hypoperfusion-induced deficits in 
learning and memory. Rats were treated for 30 days with piracetam 600mg/kg 
per day after ligature of bilateral carotid arteries. The Sham-operated group was 
only treated with saline without induction of hypoperfusion. The Morris water 
maze was performed with four trials per day during 5 days for the acquisition test 
(A), and performed with four trials on day 6 without the platform retention test (n 
= 10 ± SEM) (B). Representative examples of typical swim-tracking pathways in 
probe trial on training day 6 no platform (C). (n = 10 ± SEM). Data are reproduced 
from He et al. (2008) with permission. *p < 0,01 vs. Sham-operated, and #p < 0.05 
vs. control hypoperfusion. Tukey’s test following a repeated ANOVA.
Omin
Sham-
operated
Piracetam-
treated
HP
I
II
III
IV
V
VI
30min after HFS
300
Sham-operted
HP
Piracetam-treated
250
200
P
S
 
a
m
p
l
i
t
u
d
e
 
(
%
)
150
100
50
0
A
B
Figure 7 | Piracetam improves LTP after cerebral hypoperfusion in CA3 
synapses. Changes in LTP after ligature of carotoids induced as described by 
He et al. (2008). The animals were treated in the Sham-operated group (I, IV) 
and in the HP group (II, V) for 30 days with saline, and in the piracetam group 
(III, VI) with 600 mg/kg per day. (A) LTP was blocked in the HP group and 
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(2008) with permission. *p < 0,01 vs. Sham-operated, and #p < 0.05 vs. 
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